Evidence map›Paper›PMID 42147216›Full record

ReviewFrontiers in oncology2026

AI-mediated ultrasound radiomics in the diagnosis and treatment of triple-negative breast cancer: research progress and future challenges.

Zhihe Wang, Yifan Wang, Tao Yu, Yan Yi, Ke Xue, Wei Xu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhihe WangDepartment of Ultrasonography, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Yifan WangSchool of Medicine, Hubei Polytechnic University, Huangshi, China.
Tao YuDepartment of Ultrasonography, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Yan YiDepartment of Medical Ultrasound, The Eighth Hospital of Wuhan, Wuhan, China.
Ke XueDepartment of Ultrasonography, First People's Hospital of Wancheng District, Nanyang, China.
Wei XuDepartment of Ultrasonography, The First Affiliated Hospital of Yangtze University, Jingzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with strong invasiveness, limited treatment options, and poor prognosis. Its early accurate diagnosis and individualized treatment are major challenges faced by the clinic. With the rapid development of artificial intelligence (AI) technology, AI-mediated ultrasonic radiomics provides new ideas for non-invasive diagnosis and treatment of TNBC. This technology integrates machine learning (ML), deep learning (DL), and radiomics methods to achieve high-throughput extraction of quantitative features from ultrasonic images and construct a predictive model capable of characterizing tumor heterogeneity. Currently, AI-driven ultrasonic radiomics for TNBC diagnosis has evolved from basic differential diagnosis to multi-subtype classification, with its diagnostic performance further improved via multimodal image fusion. For prognostic assessment, the models effectively predict patients' disease-free survival (DFS) and overall survival (OS) by integrating intratumoral and peritumoral texture features, clinicopathological indicators, and other relevant factors. Nevertheless, the translation of this technology into routine clinical practice faces multiple challenges: insufficient standardized data protocols, limited model interpretability, and lack of rigorous multicenter validation studies. In the future, research on the establishment of a standardized radiomics workflow among different devices and medical centers should be given priority as well as the research on the construction of high-performance AI models with good interpretability, and multicenter prospective clinical studies should be carried out to verify its clinical value.

Indexed as

artificial intelligenceradiomicstranslational medical researchtriple negative breast cancerultrasonography

Identifiers

PMID42147216
PMCPMC13171396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.